Company intelligence / Profile preview

ARK Diagnostics

Fremont, California, United Statesark-tdm.com ↗

Ownership: Private
Development stage: Commercial

Overview

ARK Diagnostics develops and commercializes in vitro diagnostic immunoassays for therapeutic drug monitoring and urine drug testing. Their assays are used to measure levels of various drugs in biological fluids to guide dosing decisions and improve patient outcomes. The company’s products are marketed globally and cover a range of therapeutic areas including neurology (epilepsy), pain management/opioids detection, oncology/cancer treatment monitoring as well as infectious diseases such as HIV/AIDS[1][2][3][4].

Therapeutic areas: OncologyPsychiatryNeurologyInfectious Diseases
Modalities: ImmunoassayIn vitro diagnostic test
Industry: Metabolite Diagnostics

Drug pipeline

3 assets

methotrexate

Commercial

Indications: Cancer

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on ARK Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARK Diagnostics.

Explore the full profile